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Summary Monoclonal antibody (MAb) E48 reacts with a 22kD antigen exclusively expressed in squamous
and transitional epithelia and their neoplastic counterparts. Radiolabelled with 99mTc, MAb E48 is capable of
targeting metastatic and recurrent disease in patients with head and neck cancer. In this study, the capacity of
'311-labelled MAb E48 to eradicate xenografts of human squamous cell carcinoma of the head and neck
(HNSCC) in nude mice was examined. Experimental groups received a single i.v. bolus injection of 4001lCi
MAb E48 IgG (number of mice (n = 6, number of tumours (t) = 9) or 800fiCi MAb E48 IgG (n) = 5,t = 7),
whereas control groups received either diluent (n = 3,t = 5), unlabelled MAb E48 IgG (n = 4,t = 5) or 800ysCi
131I-labelled isotype-matched control MAb (n = 6,t = 9). A 4.1-fold increase in the median tumour volume
doubling time and regression of two out of ten tumours (20%) was observed in mice treated with 4001tCi. In
mice treated with 800gCi. In mice treated with 800 lCi, two out of seven tumours (29%) showed complete
remission without regrowth during follow-up (>3 months). Median tumour volume doubling time in the
remaining five tumours was increased 7.8-fold. No antitumour effects were observed in mice injected with
diluent, unlabelled MAb E48 or 131I-labelled control MAb. In the same xenograft model, chemotherapy with
doxorubicin, 5-fluorouracil, cisplatin, bleomycin, methotrexate or 2',2'-difluorodeoxycytidine yielded a less
profound effect on tumour volume doubling time. Increases in tumour volume doubling time with these
chemotherapeutic agents were 4, 2.2, 2.1, 1.7, 0, and 2.6 respectively. Moreover, no cures were observed with
any of these chemotherapeutic agents. From the tissue distribution of 8001tCi MAb E48, the absorbed
cumulative radiation doses of tumour and various organs were calculated using the trapezoid integration
method for the area under the curve. To tumour xenografts, 12,170cGy was delivered, blood received
2,984cGy, whereas in every other tissue the accumulated dose was less than 6% of the dose delivered to
tumour. These data, describing the first radiolabelled MAb with therapeutic efficacy against HNSCC, suggest
radioimmunotherapy with MAb E48 to be a potential therapeutic modality for the treatment of head and neck
cancer.
Despite an increase in the locoregional control of head and
neck squamous cell carcinoma (HNSCC), due to improved
surgery and radiotherapy, current therapy regimens have
failed as yet to increase the 5-year survival rate of patients
with head and neck cancer (Choksi et al., 1988; Cognetti et
al., 1988). Whereas fewer patients tend to die because of
uncontrolled locoregional disease, there is an increase in the
number of distant metastases and second primary tumours.
The role of chemotherapy in these patients is limited. Res-
ponses are often observed but enhancement of survival is not
obtained. These facts justify the search for more specific and
effective therapeutical methods. Since HNSCC have an int-
rinsic sensitivity for radiation (Wessels et al., 1989a), we focus
on the use of monoclonal antibodies labelled with
radioisotopes for radioimmunotherapy (RIT). RIT of human
tumours in experimental and/or clinical settings has already
been described for various types of cancer, including colorec-
tal carcinomas (Esteban et al., 1990; Lee et al., 1990; Schlom
et al., 1991; Blumenthal et al., 1991), malignant gliomas
(Colapinto et al., 1990; Lee et al., 1988a; Lee et al., 1988b;
Williams et al., 1990), ovarian carcinoma (Stewart et al.,
1989; Ward et al., 1988), small cell lung carcinoma (Smith et
al., 1990; Smith et al., 1991; Beaumier et al., 1991), mam-
mary carcinoma (Senekowitsch et al., 1989), renal cell car-
cinoma (Wessels et al., 1989b; Chiou et al., 1988), and
cutaneous T cell lymphoma (Rosen et al., 1987; Mulshine et
al., 1991). Thusfar however, no HNSCC-specific MAbs have
been available to test the efficacy of RIT to eradicate
HNSCC xenografts in an experimental setting. Therefore, we
have developed a panel of MAbs, among which MAb E48,
raised against HNSCC (Quak et al., 1990a; Quak et al.,
1990b; Quak et al., 1992). MAb E48 recognises a 20-22kD
antigen, on normal tissues selectively expressed on stratified
squamous epithelia and transitional epithelium of the blad-
der. On tumours, reactivity is restricted to malignancies aris-
ing from these tissues. The MAb E48 defined antigen is
involved in the structural organisation of squamous epithelia,
possibly at the level of cell-cell adhesion (Schrijvers et al.,
1991). Biodistribution and imaging studies with tracer
amounts of '3'I-labelled E48 IgG and F(ab')2 fragments
already demonstrated the capacity of MAb E48 for specific
delivery of radioisotope to HNSCC xenografts (Quak et al.,
1989; Gerretsen et al., 1991). Recent data from an ongoing
phase I/II trial with intraveneously administered 99'Tc-
labelled MAb E48 F(ab')2 and IgG in patients with HNSCC
indicate that MAb E48 is highly capable of detecting metas-
tatic and recurrent disease (van Dongen et al., 1992). In the
present study we demonstrate a dose dependent growth
delay, regression and complete remission of established
tumours by injection of single doses "1'1-labelled MAb E48 in
nude mice bearing HNSCC xenografts. In this experimental
model, the efficacy of RIT was compared to the antitumour
activity of a number of clinically used or experimental
chemotherapeutic agents (Braakhuis et al., 1991).
Material and methods
Monoclonal antibodies
Monoclonal antibody E48 was raised against a SCC of the
larynx (Quak et al., 1990). Affinity-purified MAb E48 IgG
and control MAb Myoscint® IgG, raised against myosin,
were obtained from Centocor Europe Inc., Leiden, The
Netherlands. Both are murine MAbs of the IgGl sub-
class.
Xenografts
Female nude mice (NMRI, 25-32g Harlan Olac CPB, Zeist,
The Netherlands) were 8-10 weeks old at the time of the
experiments. The head and neck SCC xenograft line HNX-
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HN was established by subcutaneous implantation of tumour
fragments measuring 3 x 3 x 1 mm, in the lateral thoracic
region on both sides of nude mice. Thereafter, the xenograft
line was maintained by serial transplantation (Braakhuis et
al., 1989). The tumour from which the HNX-HN line
originates was a T4N2MO squamous cell carcinoma of the
base of the tongue from a 54-year-old female patient. As
determined by indirect immunoperoxidase staining, the exp-
ression pattern of the MAb E48 defined antigen in the HNX-
HN line was comparable to the pattern of the majority of
human HNSCC tumours (Gerretsen et al., 1991). During
experiments, food and water, with potassium iodide added to
the water to prevent thyroid accumulation of 131i, were
available ad libitum.
Iodine-131 labelling
lodination of MAb IgG was performed essentially as des-
cribed earlier (Gerretsen et al., 1991). MAb IgG in phosphate
buffered saline, pH7.4, and "3'I were mixed in a ratio of
approximately 1mg MAb: I0mCi 31I in a vial coated with
lodogen (Pierce). After 10min incubation at room
temperature, a sample was removed to determine the amount
of incorporated iodine by TCA precipitation. To the reaction
mixture, 1ml AG1-X-8 resin (BioRad) in PBS, 1% BSA was
added to absorb free iodine. To remove the resin and to
sterilize the product, the reaction mixture was filtered
through a 0.22;tm filter.
Quality control of'3'I-labelled MAb E48 IgG
After labelling, the immunoreactive fraction was at least 85%
in all experiments. Incorporated '3'I was higher than 90% in
all experiments as determined by TCA precipitation. Specific
activity of the radioimmunoconjugate varied between 5 and
0mCimg -'.
MAb IgG in vitro binding assay
The binding characteristics of radiolabelled MAb E48 IgG
were analysed in an immunoreactivity assay, essentially as
described earlier (Gerretsen et al., 1991). In short, cells of the
squamous cell carcinoma cell line UM-SCC 22B, a gift from
Dr T.E. Carey (Ann Arbor. MI, USA), were fixed in 1%
paraformaldehyde and five serial dilutions, ranging from
5 x 10' cells/tube to 3.1 x 105 cells/tube, were made with 1%
bovine serum albumin (BSA) in 10mM phosphate-buffered
saline (PBS). To the tubes, 10,000cpm of the labelled MAb
IgG was added and incubated 120min at room temperature.
To a duplicate of the last sample, excess unlabelled MAb
IgG was added to determine non-specific binding. Cells were
spun down and radioactivity in the pellet and supernatant
was determined in a gamma counter and the percentage
bound and free radiolabelled MAb was calculated (LKB-
Wallac 1218 CompuGamma). Data were graphically
analysed in a modified Lineweaver-Burke plot and the
immunoreactive fraction was determined by linear extrapola-
tion to conditions representing infinite antigen excess.
Toxicity studies
The maximum tolerated dose of each of the
chemotherapeutic agents, corresponding to a weight loss
between 5 and 15%, was determined as described earlier
(Braakhuis et al., 1989; Braakhuis et al., 1991). In the same
way, the maximum tolerated dose of '31I-labelled MAb E48
was determined. Nude mice without xenografts were injected
with diluent (PBS) or with increasing doses of "3'I-labelled
MAb E48 IgG. Total body dose was determined in a dose
calibrator. Total accumulated radiation dose was calculated
as described in the section 'Dosimetry calculations'. The
weight of the mice was measured daily over a period of 4
weeks, at which timepoint no radioactivity could be
detected.
In vivo biodistribution studies
Biodistribution studies with tracer dose '31I-labelled MAb
E48 IgG in nude mice bearing HNX-HN xenografts have
previously been described (Gerretsen et al., 1991; Quak et al.,
1989). To compare the biodistribution of a therapeutical dose
with a tracer dose, 28 mice bearing xenografts of a size
comparable with the tracer dose study were injected i.v. with
80011Ci 'I-labelled MAb E48 IgG. At the time of injection
the estimated xenograft volume was 323 ± 244mm3 as deter-
mined by measuring the tumour in three dimensions with
calipers ((L x W x H)/2) (versus 352 ± 207.5 in the tracer
dose study). Mice were bled, killed and dissected 2, 5 and 8h
and 1, 3, 7, 10, 14, 21, 28 and 35 days after i.v. injection.
Organs were immediately removed, placed in 5ml plastic
tubes and weighed. Samples were taken from blood, urine,
tumour, liver, spleen, kidney, heart, stomach, ileum, colon,
bladder, sternum, muscle, lung, skin and tongue. After
weighing, radioactivity in all organs and tumours was
counted in a gamma counter. The antibody uptake in the
tumour and other tissues was calculated as the percentage of
the injected dose per gram of tissue (% ID.g-1).
Radioimmunotherapy
Mice bearing 1 or 2 xenografts with a volume between 50
and 250mm3 were given a single intravenous injection of 400
(n = 6,t = 9) or 800 (n = 5,t =7)psCi'3I-labelled MAb E48
IgG. Control groups were given diluent (n = 3,t = 5),
unlabelled MAb E48 IgG (n = 4,t = 5; amount equivalent to
800gsCi "3'I-labelled MAb IgG) or 800j.Ci "3'I-labelled cont-
rol MAb IgG (n = 6,t = 9). Groups were randomised for
initial tumour volume, for diluent 90 ± 68 (mean ± s.e.m.),
for unlabelled MAb E48 96 ± 26, for 800fLCi '31I-labelled
control MAb 122 ± 106, for 400ftCi '31I-labelled MAb E48
93 ± 40, and for 8001tCi "3'I-labelled MAb E48 118 ± 32. At
day 1, 2, and 3, cages were cleaned to remove excreted
radioactivity and therafter this was done weekly. During the
first week mice were weighed daily and tumour size was
determined daily as described earlier. After the first week
weight and tumour size were determined twice a week. At the
same timepoints whole body dose was measured in a dose
calibrator. Mice were sacrificed when tumour size exceeded
1000mm3.
Dosimetry calculations
Dosimetry calculations were performed using the data of the
biodistribution of 800jaCi '3ll-labelled MAb E48 IgG. The
absorbed cumulative radiation dose for tumour and various
organs was calculated using the trapezoid integration method
for the area under the curve (Badger et al., 1986). Due to the
therapeutic effect of the dose, tumours at day 35 had almost
completely regressed and were thus not included in dosimetry
calculations. The final segment of the area under the curve
was calculated based on the biological halflife: dose of last
segment = dose previous segment (day 21-day 28) x 0.693.(tj
in previous segment)-'. cGy were further calculated by mul-
tiplying the#iCi.h.g-' by the g.cGy.(pCi.h)- factor published
by the Medical Internal Radiation Dose committee for "'lI of
0.4313 (Dilman, 1969).
Chemotherapy
All drugs were injected at the maximum tolerated dose level
(5-15% weight loss). Schedules were based on results of
experiments performed in previous studies (Braakhuis et al.,
1989; Braakhuis et al., 1991). Mean number of mice and
tumours in all schedules was 5 and 7, respectively. The
volume of the tumours at the time of injection ranged
between 50-150mm3. The following doses and injection
schedules were applied: Doxorubicin (DOX, Farmitalia,
Bournonville-Pharma, Almere, The Netherlands) at
8mgkg-' i.v. at day 0 and 8; dFdC (2',2'-
difluorodeoxycytidin, Gemcitabine, LY 188011, Lilly498 M. GERRETSEN et al.
Research, Windlesham, Surrey, United Kingdom) at
120mgkg-' i.p. at day 0, 3, 6 and 9; 5-FU (Fluorouracil
Roche, Hoffman-La Roche, Mijdrecht, The Netherlands) at
125mgkg-' i.p. at day 0 and 8; CCDP (Platinol, Bristol
Meyers, Weesp, The Netherlands) at 5mgkg-' i.v. at day 0, 8
and 15; BLEO (Bleomycin, Lundbeck, Amsterdam, The
Netherlands) at 15mgkg-' i.p. at day 0, 1, 2, 3 and 4, and
methotrexate (Ledertrexate, Lederle, Etten-Leur, The
Netherlands) at 1.8mgkg-1 i.p. at day 0, 1, 2, 3 and 4.
Evaluation oftherapeutic efficacy
Tumour bearing mice were treated with RIT or
chemotherapy when most tumours reached a volume of at
least 50mm3 (range 50-250mm3). Tumours smaller than
50mm3 at the time of injection were not included in the
determination of the tumour volume doubling time because
of inaccuracy in measuring these tumours. Tumour growth
was expressed as the tumour volume at each timepoint
relative to the tumour volume at day 0. Efficacy of RIT as
well as chemotherapy was expressed by means of the
tumour growth delay factor (GDF), defined as (TD,-TDC)/
TDC(TDt = median tumour volume doubling time of treated
mice, TD, = median tumour volume doubling time of control
mice). Prolonged survival (survival defined as the time period
between day 0 and the timepoint of sacrifice, being when
tumour size exceeded 1000mm3) was determined by compar-
ing experimental groups with treatment groups using the
Mann-Whitney U-test.
Results
Toxicity studies
The total cumulative whole body radiation dose for 220ptCi,
420OCi, 670jCi and 840pCi '311-labelled MAb E48 IgG was
8,343, 11,673, 22,693 and 28,987cGy, respectively. Besides
loss of weight, no adverse reactions were observed. Loss of
weight occurred immediately in the 420, 670 and 8401ACi
groups, and reached a maximum of 2.5, 10 and 10% respec-
tively (Figure 1). Recovery of weight was observed for all
mice from day 13 on and reached control values within 4
weeks. Based on these data, the maximum dose for therapy
experiments was set at 800jsCi.
Biodistribution
The biodistribution of 800yCi "3'1-labelled MAb IgG is
shown in Figure 2. Radioactivity measured in the blood is
23% IDg-' after 2h and is cleared with a Tio of 14.3h and a
Tip of 127.7h. Radioactivity accumulated rapidly in tumours
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Figure 1 Toxicity of '31I-labelled MAb E48 in nude mice without
xenografts monitored as the bodyweight relative to day 0, for
diluent (0), 220 LCi (0), 420fiCi (A), 670JCi (0) and 840pCi
(U). Values are the mean of four mice per dose, standard devia-
tions were less than 3%.
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Figure 2 Biodistribution of 800sCi '3'I-labelled MAb E48 in
nude mice bearing HNX-HN xenografts. Mice were bled, killed
and dissected 2, 5 and 8h and 1, 3, 7, 10, 14, 21, 28 and 35 days
after injection and the percentage injected dose per gram
(%IDg-1) was calculated and plotted versus time. Tumour (0),
blood (M) and lung (A) are shown.
and reached a maximum of 19.4 ± 2.9% IDg-' after 3 days.
Activity is retained in the tumour up to 8.1 ± 3.5% IDg-' at
day 28. No specific accumulation is observed in any other
tissue.
Dosimetry calculations
The absorbed cumulative radiation dose for tumour and
various organs is shown in Figure 3. Based on the area under
the curve of the biodistribution data of 800pCi 31I-labelled
MAb E48 IgG the absorbed radiation dose to tumours in the
group receiving 800 Ci was 12,170cGy, whereas blood
received only 2,984cGy. Other tissues received the following
dose: lung; 662cGy; kidney; 607cGy; spleen: 581cGy; blad-
der: 571cGy; heart: 543cGy; colon: 424cGy; ileum: 405cGy;
sternum: 405cGy; liver: 403cGy; muscle: 276cGy; stomach:
251 cGy.
Evaluation oftherapeutic efficacy
Tumour growth expressed as the tumour volume at each
timepoint relative to the tumour volume at day 0 for control
and treatment groups is shown in Figure 4. Tumours in the
groups receiving unlabelled MAb E48 IgG (Figure 4a),
800,uCi '31I-labelled control MAb IgG (Figure 4b) and
diluent (Figure 4c) all showed exponential growth. Median
tumour volume doubling times in the group receiving diluent
or unlabelled MAb E48 IgG was 5.5 days. Median tumour
volume doubling time in the group receiving 800;LCi '31I-
labelled control MAb showed a minimal, statistically
insignificant increase. All tumours in the group receiving
400fCi '31I-labelled MAb E48 IgG (Figure 4d) showed delay
of growth with a median tumour volume doubling time of
22.6 days, while two out of nine tumours showed regression.
All tumours in the group receiving 800 Ci '3'I-labelled MAb
E48 IgG (Figure 4e) showed regression, with a median
tumour volume doubling time of 43 days. Moreover, in this
group, two out of seven tumours showed complete remission
without regrowth during follow-up (>3 months). After
sacrificing these animals, no evidence of tumour could be
detected at the site of implantation. The tumour growth
delay factor calculated for the 400 and 800sLCi groups was
3.1 and 6.8, respectively. Weight loss in experimental groups
did not exceed 15% at any timepoint. When compared with
the tumour growth delay factor of chemotherapeutic agents
like adriamycin (3.0),5-fluorouracil(1.2), cisplatin (1.1),
bleomycin (0.7), methotrexate (0) and 2',2'-difluorodeoxy-
cytidine (1.6), established in the same HNX-HN xenograft,
RIT shows a very high therapeutic efficacy (Figure 5). No
cures were observed with chemotherapeutic agents. Pro-EXPERIMENTAL RADIOIMMUNOTHERAPY WITH '3'I-LABELLED MAb E48
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Figure 3 Total accumulated radiation dose in I1&cGy, calculated
using the trapezoid integration method for the area under the
curve. Tu, tumour; Blo, blood; Bla, bladder; Lu, lung; Ki,
kidney; Sp, spleen; He, heart; Li, liver; Co, colon; Sto, stomach;
I1, ileum; Ste, sternum; Mu, muscle.
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Figure 4 Effects of unlabelled MAb E48, n = 4, t = 5 a, '3'-
labelled control MAb, n = 6, It
= 9 b, diluent, n = 3, t = 5 c,
4001Ci '3'I-labelled MAb E48, n = 6, t = 9 d, and 800tCi '3'I-
labelled MAb E48, n = 5, t = 7 e on the growth of HNX-HN
xenografts, expressed as the tumour volume during therapy rela-
tive to the tumour volume at the start of the therapy. Mice were
sacrificed when tumours exceeded 1000mm3, n = number of
animals, t = number of tumours. * = complete remission without
regrowth during follow up (>3 months).
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Figure 5 Antitumour effect of RIT in comparison with
chemotherapy in HNX-HN xenografts. Antitumour effect was
expressed as the tumour growth delay factor (see: Material and
methods). DOX, doxorubicin; dFdC,2',2'-difluorodeoxcytidine; 5-
FU, 5-fluorouracil; CP, cisplatin; BLEO, bleomycin; MTX,
methotrexate (* = 0).
longed survival, as determined by the Mann-Whitney U-test,
was significant for both RIT groups as compared to control
groups (P <0.01).
Discussion
Therapeutic efficacy of radiolabelled MAbs in the nude
mouse model has been described for several tumour types.
Although clinical radioimmunoscintigraphy studies for the
detection of HNSCC have been reported with "'In-labelled
anti-epidermal growth factor receptor (Soo et al., 1987) and
with "'In-labelled anti-carinoembryonic antigen (Kairemo &
Hopsu, 1990; Kairemo & Hopsu, 1990), no reports are
available on therapy experiments of HNSCC xenografts with
radiolabelled MAbs. Here we present the first data on RIT of
HNSCC. As a first approach to assess the potential of
radiolabelled MAb E48 in eradicating HNSCC xenografts,
therapy experiments, consisting of single bolus injection of
two different doses, were designed in a straight forward
manner. Dosimetry calculations were based on the biodis-
tribution of a therapeutic dose, since continued tumour
growth in biodistribution experiments with tracer dose may
well result in underestimation of the radiation dose up to
35-52% (Lee et al., 1990; Badger et al., 1986). In our
studies, no differences in biodistribution between tracer and
therapeutic doses were observed. In tracer dose studies how-
ever, no data were available during the first 12h and after
day 7, whereas in this study data were obtained from 2h p.i.
up to 35 days, allowing more accurate dosimetry calcula-
tions. A remarkable good retention of MAb E48 was
observed with 8.1 ± 3.5%IDg-' at day 28 after injection.
Although numerous reports with 131I-labelled MAb IgG or
F(ab')2 have been described with anti-tumour effects, only
few studies achieve complete remissions after single bolus
injections. Wessels et al. reported complete remissions of
renal cell carcinoma xenografts after single bolus injection of
600[,Ci 131I-labelled MAb IgG (Wessels et al., 1989), whereas
Sharkey et al. observed no regrowth of colon carcinoma
xenografts after a single injection of 1 mCi MAb IgG
(Sharkey et al., 1987). Lee et al. obtained apparent cures of
mice with intracranial glioma xenografts after a single injec-
tion of 1.25mCi MAb IgG (Lee et al., 1988). Complete
ablation of highly radiation sensitive neuroblastoma xeno-
grafts was achieved with a single injection of 1 mCi IgG by
the group of Cheung et al. (Cheung et al., 1986). Buchegger
et al. completely eradicated xenografts of colon carcinomas
with single injections of 2,200-2,800.tCi, but instead of IgG,
pooled F(ab')2 fragments of three different anti-CEA MAbs
were used (Buchegger et al., 1989). Other successful studies
applied fractionated protocols (Smith et al., 1991;
Senekowitsch et al., 1989; Schlom et al., 1990; Buchegger et
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al., 1989). In our study, single injections of 400 or 800yCi
"3'1-labelled E48 MAb IgG showed pronounced anti-tumour
effects, resulting in complete remissions of two out of seven
tumours in the group receiving 800fiCi "3'I-labelled MAb E48
IgG. No remnant tumour could be detected when mice were
sacrificed after 3 months follow-up. These cures might very
well be due to the intrinsic sensitivity of head and neck
tumours for radiation (Wessels et al., 1989a). In addition, the
accumulated dose, 12,170cGy, in tumour tissue as a result of
a single bolus injection 800yCi was very high, reflecting the
excellent targetting and retention characteristics of MAb E48
in this experimental model.
Therapeutic efficacy of RIT has been found to be inversely
correlated with tumour size (Scholm et al., 1991; Lee et al.,
1988; Sharkey et al., 1987). Accordingly, RIT has the poten-
tial to be the most useful in adjuvant therapy when minimal
disease is present (Sharkey et al., 1987; Langmuir & Suther-
land, 1988). In the case of head and neck cancer this would
apply to patients with stage III and IV disease. In these
patients local recurrences occur in 50-60%, while 15-25%
develop distant metastases after surgery and/or radiotherapy
(Choksi et al., 1988). Unfortunately, no relevant metastatic
model for HNSCC is available. In our study, the correlation
between tumour size and therapeutic effect could not be
determined due to the selected size range.
In several studies, an increase in therapeutic efficacy com-
bined with a decrease in toxicity has been observed when
total dose was given in multiple fractions (Buchegger et al.,
1990; Buchegger et al., 1989; Colapinto et al., 1990; Smith et
al., 1991; Schlom et al., 1990). Therefore, the efficacy of RIT
with MAb E48 with respect to growing, established HNX-
HN xenografts will be further investigated comparing single
injection regimen to multiple injection regimens. Further-
more, since 131I is not the isotope ofchoice in clinical applica-
tions because of the low percentage therapeutic P-emission
(32%) and the high percentage damaging y-radiation (66%),
and because of the rapid dehalogenation of "1'I-labelled con-
jugates, we have developed a MAb E48 radioimmunocon-
jugate labelled with "86Re, an isotope with a high percentage
P-emission (90%) and low percentage y-emission (8%). MAbs
labelled with this isotope have already been described in
tumour localisation and tumour therapy studies (Beaumier et
al., 1991; Goldrosen et al., 1991). MAb E48 labelled with this
isotope will be tested in the HNX-HN xenograft model.
Thusfar, clinical results with chemotherapy have been
disappointing with respect to the effect on 5-year survival of
patients, despite the number of trials over the past 10 years
(Choksi et al., 1988; Snow, 1991). In our HNX-HN xenog-
raft model, a number of conventional drugs, known to pro-
duce remissions in patients with head and neck cancer, and
one experimental chemotherapeutic agent have been
evaluated (Braakhuis et al., 1991) unpublished data). In the
dose schedules described, none of the chemotherapeutic
agents caused tumour growth delay factors higher than those
obtained with either 800yCi or 400fiCi 3'I-labelled MAb
E48 IgG. Furthermore, no cures were observed with these
chemotherapeutic agents.
One of the limitations of the nude mouse xenograft model
for RIT studies with radiolabelled MAbs is the absence of
antigen expression in normal tissues. The presence of the
MAb E48 defined antigen in normal tissues in the clinical
situation will obviously influence the pharmacokinetics and
biodistribution of radiolabelled MAb E48. In clinical
radioimmunoscintigraphy studies using 9'Tc-labelled MAb
E48 (Fab')2 fragment we observed uptake of radioactivity in
normal oral mucosa and adrenal glands (van Dongen et al.,
1992). Uptake in these tissues seems to be diminished when
using whole IgG. Most clinical trials with radiolabelled MAb
for diagnosis or therapy of solid neoplasms have reported
MAb uptake in large tumours in the range of
0.001-0.01%IDg-l (Goldenberg, 1991; Epenetos & Kosmas,
1989). Preliminary data on the localisation of 'mTc-labelled
MAb E48 IgG indicate accumulation of the conjugate in
tumours of 0.5-4.0cm diameter up to a mean %IDg-' of
0.03 at 44h (range: 0.0143-0.0823, number of patients = 7).
This looks very promising indeed, when taking into account
the higher accumulation of MAbs in small tumour loads.
Chatal et al. reported on the biodistribution of "'In-labelled
MAb OC125 intraperitoneally injected into patients with
ovarian carcinoma, demonstrating low accummulation in
large tumours (0.0014-0.0032 %IDg-') but significantly
higher accumulation in small tumour nodules (0.13 ± 0.08
%IDg-') and malignant cell clusters (median 0.33 with a
maximum of 4.16 %IDg-') (Chatal et al., 1989). Assuming
that this size correlation also applies for head and neck
tumours and assuming that patients will tolerate a dose of
lOOmCi of '311-labelled MAB E48 (or an equivalent dose of
'86Re-labelled MAb E48) (Rosen et al., 1987; Ward et al.,
1988), achieving radiation doses in tumour tissue enabling
elimination of minimal disease lies within reach.
Our data, showing the capacity of a single bolus injection
'3'I-labelled MAb E48 to eradicate HNSCC xenografts in
nude mice, present the first successful RIT results for head
and neck squamous cell carcinoma. Together with data from
an ongoing phase I clinical trial in our hospital, showing the
capacity of 99'Tc-labelled MAb E48 (F(ab')2 fragment and
IgG in detecting metastatic and recurrent disease, this
indicates the potential of radiolabelled MAb E48 for
radioimmunotherapy of patients with head and neck
cancer.
This work was supported in part by Centocor Europe Inc., Leiden,
The Netherlands.
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